MedPacto Expands Overseas Partnering at 'China Bio'

Innovative drug development company MedPacto announced on the 16th that it will participate in the 'China Bio Partnering Forum 2025' to explore technology licensing and expand joint research.

'China Bio' will be held for two days from the 23rd to the 24th in Shanghai, China.

MedPacto's business development executives, along with President Woo Jung-won, will personally attend and hold partnering meetings with numerous multinational pharmaceutical companies and leading Chinese biotech firms. They will explain the recently refined pipeline development strategies, current status, and research achievements, and promote partnerships related to technology transfer and joint clinical trials.

A MedPacto representative said, "We will review the early approval strategy for the anticancer drug pipeline 'Vactosertib' and establish joint development partnerships for new combination therapies. Development discussions for the new pipelines 'MP2021' and 'MP010' will also take place."

China Bio is the largest bio industry conference in China, which started in 2009. It brings together global bio and pharmaceutical companies, investors, and research institutions to seek partnerships and exchange technologies.

As China has recently emerged as a rising power expanding its influence in the global new drug development market, this event will host a record number of over 800 companies from 30 countries.

MedPacto will also actively promote the introduction of new pipelines, technology licensing, and joint development partnering at 'BIO USA' to be held in June.

This content was produced with the assistance of AI translation services.